Table 5 Patient characteristics by relapse
From: Vision loss in patients with giant cell arteritis treated with tocilizumab
All | No relapse | Relapse | p value | |
|---|---|---|---|---|
n (%) or median (IQ range) | n (%) or median (IQ range) | n (%) or median (IQ range) | ||
Total N | N = 186 | N = 119 | N = 67 | |
Female | 116 (62%) | 77 (65%) | 39 (58%) | 0.432 |
Age at diagnosis | 71.0 (63.0; 77.0) | 71.0 (66.0; 77.0) | 69.0 (62.0; 76.0) | 0.174 |
Cranial symptoms (incl. visual imp.) | 124 (67%) | 81 (68%) | 43 (64%) | 0.629 |
Visual symptoms | 70 (38%) | 49 (41%) | 21 (31%) | 0.209 |
Vision loss | 21 (11%) | 15 (13%) | 6 (9%) | 0.630 |
Headache | 93 (50%) | 58 (49%) | 35 (52%) | 0.760 |
Jaw claudication | 48 (26%) | 33 (28%) | 15 (22%) | 0.487 |
Scalp tenderness | 42 (23%) | 23 (19%) | 19 (28%) | 0.201 |
Claudication of tongue | 2 (1%) | 2 (2%) | 0 (0%) | 0.537 |
Fever ≥ 38 °C | 35 (19%) | 20 (17%) | 15 (22%) | 0.435 |
Weight loss > 2 kg within 4 weeks | 50 (27%) | 29 (24%) | 21 (31%) | 0.389 |
Night sweat | 33 (18%) | 22 (18%) | 11 (16%) | 0.843 |
Polymyalgia rheumatica | 90 (48%) | 58 (49%) | 32 (48%) | 0.878 |